Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 4/20 | 0.54 |
| ▸ | RXRA | P19793 | 8/20 | 0.52 |
| ▸ | RXRB | P28702 | 8/20 | 0.52 |
| ▸ | RXRG | P48443 | 8/20 | 0.52 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18409339 | 0.88 | HTR6 (0.52) | HTR6RXRARXRBRXRGNR4A2 | |
| SCHEMBL18409637 | 0.88 | CDK4 (0.46) | HTR6RXRARXRBRXRGPTPN1 | |
| SCHEMBL18409633 | 0.88 | PTPN1 (0.45) | HTR6RXRARXRBRXRGNR4A2 | |
| SCHEMBL22692981 | 0.87 | NR4A2 (0.46) | HTR6RXRARXRBRXRGNR4A2 | |
| SCHEMBL18409642 | 0.86 | NR4A2 (0.53) | HTR6RXRARXRBRXRGNR4A2 | |
| SCHEMBL18409702 | 0.85 | HTR6 (0.43) | HTR6RXRARXRBRXRGNR4A2 | |
| SCHEMBL18409723 | 0.85 | RXRA (0.54) | HTR6RXRARXRBRXRGPTPN1 | |
| SCHEMBL18409645 | 0.85 | RXRA (0.54) | HTR6RXRARXRBHTR1AHTR2A | |
| SCHEMBL18409685 | 0.81 | PTPN1 (0.46) | HTR6RXRARXRBRXRGNR4A2 | |
| SCHEMBL18409641 | 0.81 | CDK4 (0.47) | HTR6RXRARXRBRXRGPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10844051-B2 | Substituted oxazoles for the treatment of cancer | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY | 2020-11-24 | — | — | US | disclosed |
| US-20180208586-A1 | COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCERS AND OTHER MEDICAL CONDITIONS | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2018-07-26 | — | — | US | disclosed |
| WO-2017011920-A1 | COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCERS AND OTHER MEDICAL CONDITIONS | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2017-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180208586-A1 | COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCERS AND OTHER MEDICAL CONDITIONS | VHL, TP53, CD44 | HTR6 4055/4885RXRA 172/4885RXRB 232/4885 |
| US-10844051-B2 | Substituted oxazoles for the treatment of cancer | OXA1L, PDCD1, MCL1 | HTR6 4248/4885RXRA 1247/4885RXRB 1153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.